Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases

Abstract

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

1 . A method of treating a cardiovascular disease comprising administering a therapeutically effective amount of an isolated antibody reactive with TLR3 to a patient in need thereof for a time sufficient to treat the cardiovascular disease. 
     
     
         2 . The method of  claim 1 , wherein the isolated antibody reactive with TLR3 antibody comprises heavy chain complementarity determining regions 1, 2 and 3 (HCDR1, HCDR2, HCDR3) having amino acid sequences shown in SEQ ID NOs: 70, 77 and 72 and light chain complementarity determining regions 1, 2 and 3 (LCDR1, LCDR2, LCDR3) having amino acid sequences shown in SEQ ID NOs: 67, 68 and 78. 
     
     
         3 . The method of  claim 1 , wherein the isolated antibody reactive with TLR3 antibody comprises heavy chain complementarity determining regions 1, 2 and 3 (HCDR1, HCDR2, HCDR3) having amino acid sequences shown in SEQ ID NOs: 82, 86 and 84 and light chain complementarity determining regions 1, 2 and 3 (LCDR1, LCDR2, LCDR3) having amino acid sequences shown in SEQ ID NOs: 79, 80 and 87.